Photo of Lea Webb
D New York Senate · District 52 On the 2026 ballot

Sen. Lea Webb

Compare
Total votes
8,145
all sessions
Attendance
99%
87 missed
Near the chamber average
With party
98%
of cast votes
Higher than 83% of chamber peers
Bipartisan score
1%
crosses aisle rarely
Lower than 85% of chamber peers
Sponsored
2,210
bills & resolutions
Higher than 92% of chamber peers
Committees
10
assignments
2,210 bills and resolutions

Sponsored bills

Total
2,210
Primary
294
Co-sponsor
1,916
This page
2,210
matching current filters
Co-sponsor S 1752
In committee · New York Senate · Co-sponsor
Expands the definition of crops, livestock and livestock products to include cannabis

Maddy summaryThis bill amends state agricultural law to officially classify cannabis as a crop, livestock, or livestock product. By adding a specific paragraph to the existing agriculture and markets law, it brings cannabis under the same regulatory definitions used for traditional farming commodities. The change takes effect immediately and allows cannabis to be treated consistently with other agricultural goods within the state's legal framework.

In committee May 15, 2024 1 co-sponsor
Co-sponsor S 2398
In committee · New York Senate · Co-sponsor
Establishes a statewide emergency and crisis response council

Creates statewide emergency and crisis response council to work in conjunction with the commissioners of mental health and addiction services to jointly approve emergency and crisis services plans submitted by local governments, and provide supports regarding the operation and financing of high-quality emergency and crisis services provided to persons experiencing a mental health, alcohol use, or substance use crisis.

In committee May 15, 2024 1 co-sponsor
Co-sponsor S 4513
In committee · New York Senate · Co-sponsor
Preserves access to affordable drugs

Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, shall be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filer's product for any period of time.

In committee May 15, 2024 1 co-sponsor
Showing 1,471 to 1,480 of 2,210 bills